Vertex to acquire Crinetics for $10B; CRNX shares surge 99%

Danielle Liverance Thu, July 9, 2026 at 10:29 AM PDT | 3 min read

Quick Read

• Vertex's $85-per-share all-cash acquisition sent CRNX up 116% on a franchise the company projects will exceed $5 billion in peak annual sales.
• NBIX gained 6% and CORT rose 5% as investors repriced endocrine rare-disease specialists as potential M&A targets following the deal.
• Trading just under the $85 cash offer, CRNX upside is capped unless a competing bid emerges before the expected Q3 2026 close.

Crinetics Pharmaceuticals (NASDAQ: CRNX) shares have climbed 99% this week, from $42.03 at Monday's close to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ: VRTX) agreed to acquire it.

Vertex's $10 Billion All-Cash Bid Fuels the Surge

The catalyst arrived after the market close on July 6: Vertex agreed to buy Crinetics for approximately $10 billion, or $85.00 per share in all cash. The transaction was unanimously approved by both boards and is expected to close in Q3 2026. Vertex plans to finance the deal with cash and debt.

The prize is Crinetics' endocrine franchise:

• PALSONIFY (paltusotine) — the first once-daily oral somatostatin receptor type 2 nonpeptide agonist for acromegaly. It cleared the FDA in September 2025 and won European Commission approval in April 2026. Q1 2026 product sales hit $10.31 million, with 263 unique prescribers and roughly 70% of patients on reimbursed therapy.
• Atumelnant — a Phase 3 candidate for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome.

Vertex projects the acquired assets could deliver over $5 billion in peak annual sales and contribute earnings accretion by 2029.

Endocrine Peers Get a Re-Rating Look

Vertex is stepping outside cystic fibrosis and building a fifth business group in endocrine diseases. That validation puts a fresh spotlight on the small cluster of rare-disease specialists in the same neighborhood. Vertex shares themselves barely moved on the week, gaining 0.08% to $498.43, reflecting investor caution about the price tag.

The most direct competitive read-throughs are into Cushing's syndrome and CAH:

| Company | Ticker | Weekly Gain | Key Asset | |---------|--------|-------------|-----------| | Neurocrine Biosciences | NBIX | +6.24% | CRENESSITY (crinecerfont) for classic CAH; $153.30M in Q1 2026 revenue | | Corcept Therapeutics | CORT | +5.04% | Relacorilant for Cushing's syndrome; newly approved ovarian cancer indication Lifyorli | | Ascendis Pharma | ASND | +3.51% | YORVIPATH and YUVIWEL for endocrine rare diseases |

Those moves arrive against a backdrop where a scaled acquirer just paid roughly $85 per share for a company whose analyst target sat at $83.73 and whose full-year 2026 revenue is pegged around $69 million. Investors sifting for the next endocrine tuck-in are exactly the audience that reads through to names like these — one reason breakout-driven M&A watchlists get updated after weeks like this one.